DURHAM, N.C., August 8, 2016 – Arcato Laboratories, developer of OraWaxTM, a revolutionary new treatment for the discomfort caused by orthodontic braces, has been selected to participate at the CED Tech Venture Conference, being held September 13-14, 2016 at the Convention Center in Raleigh, North Carolina. Arcato will have a booth featuring its groundbreaking technology in the Demo Room of the conference.
“The technology platform of Arcato Laboratories is based upon a patented method of delivering a local anesthetic to oral mucosal membranes over a sustained period of time,” said Meldrum. “The Arcato technology platform has many applications for other types of pain relief, but the OraWax™ product alone has an estimated market of about $400 million per year,” he added.
As the premier event for technology entrepreneurs and investors in the Southeast, CED Tech Venture Conference attracts some of the most innovative minds from across the nation to Raleigh, North Carolina, recently ranked #5 tech hotspot.
Arcato is currently raising $1 million in a Series B round of financing, to complete 510(k) FDA regulatory clearance for OraWax™, and launch the product in the United States.
About Arcato Laboratories
Arcato Laboratories, a leader in the sustained release of anesthetics, is commercializing proprietary products to serve specialty oral healthcare practitioners, such as orthodontists and oral surgeons. Arcato’s first product, a medical device named OraWax™, targets orthodontists and their patients as the first effective treatment for oral discomfort caused by orthodontic appliances (braces). For more information on investing, please visit our Investor Relations Page.